Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Develo** an …

Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Summary Background Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically
active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe …

Abstract Development of a highly effective vaccine or antibodies for the prevention and
ultimately elimination of malaria is urgently needed. Here we report the isolation of a number …

Vaccination with infectious Plasmodium falciparum (Pf) sporozoites (SPZ) administered with
antimalarial drugs (PfSPZ-CVac), confers superior sterilizing protection against infection …

Consistent, high-level, vaccine-induced protection against human malaria has only been
achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites …

A live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ
Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with …

Highlights•First malaria vaccine RTS, S induces anti-sporozoite antibodies to protect
children.•Whole-sporozoite vaccines induce T cells and antibodies and confer field …

Abstract An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ
Vaccine, is highly protective against controlled human malaria infection (CHMI) 3 weeks …